3,000 Shares in DaVita Inc. $DVA Acquired by Performance Wealth Partners LLC

Performance Wealth Partners LLC purchased a new position in shares of DaVita Inc. (NYSE:DVA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,000 shares of the company’s stock, valued at approximately $667,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. NewEdge Advisors LLC grew its position in DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of DaVita by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after buying an additional 28,739 shares during the last quarter. Cerity Partners LLC boosted its stake in shares of DaVita by 7.0% during the second quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock worth $376,000 after buying an additional 172 shares during the period. Bank of Nova Scotia grew its holdings in shares of DaVita by 3.8% during the second quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock worth $686,000 after buying an additional 176 shares during the last quarter. Finally, Natixis grew its holdings in shares of DaVita by 80.9% during the second quarter. Natixis now owns 7,297 shares of the company’s stock worth $1,039,000 after buying an additional 3,264 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on DVA shares. TD Cowen raised DaVita from a “hold” rating to a “buy” rating and upped their price objective for the company from $201.00 to $220.00 in a research note on Friday, August 7th. Oppenheimer set a $220.00 target price on DaVita in a report on Friday, August 7th. UBS Group upped their price target on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Raymond James Financial set a $220.00 price target on DaVita in a report on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $265.00 price objective on shares of DaVita in a research report on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $221.75.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This represents a 12.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.90% of the stock is currently owned by company insiders.

DaVita Trading Down 2.0%

Shares of DVA opened at $176.47 on Tuesday. The stock’s 50 day moving average is $217.03 and its two-hundred day moving average is $180.11. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $247.49. The firm has a market capitalization of $11.26 billion, a PE ratio of 14.44, a P/E/G ratio of 0.60 and a beta of 0.88.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. During the same period in the previous year, the business earned $2.95 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts predict that DaVita Inc. will post 14.57 EPS for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.